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Methods: We evaluated the discriminative ability of a genetic risk score (GRS) covering 22 published
genetic risk loci forAD in1162Flanders-BelgianADpatients and1019 controls andassessedcorrelations
with family history, onset age, and cerebrospinal fluid (CSF) biomarkers (Ab1–42, T-Tau, P-Tau181P).
Results: A GRS including all single nucleotide polymorphisms (SNPs) and age-specific APOE ε4
weights reached area under the curve (AUC) 0.70, which increased to AUC 0.78 for patients with
familial predisposition. Risk of AD increased with GRS (odds ratio, 2.32 (95% confidence interval
2.08–2.58 per unit; P , 1.0e215). Onset age and CSF Ab1–42 decreased with increasing GRS
(Ponset_age 5 9.0e
211; PAb 5 8.9e
27).
Discussion: The discriminative ability of this 22-SNP GRS is still limited, but these data illustrate
that incorporation of age-specific weights improves discriminative ability. GRS-phenotype
correlations highlight the feasibility of identifying individuals at highest susceptibility.
 2015 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Keywords: Alzheimer’s disease; Genetic risk profile; Genotype-phenotype correlation; CSFAb1–42; Onset age; Family history1. Introduction
Alzheimer’s disease (AD) is an incapacitating, incurable
disease characterized by a progressive loss of cognitive
functions. It has a long disease course and ultimately requires
fulltime medical care. Aside from drugs that temporarily
relieve symptoms, no treatment exists for AD. With theno competing interests.
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commons.org/licenses/by-nc-nd/4.0/).growing proportion of people .65 years, and the high costs
associated with care for AD patients, the future impact of AD
on society and public health is of great concern. Projection
models demonstrate that even therapies with a modest effect
could decrease the number of AD patients by millions [1].
AD has a long prodromal phase [2], necessitating
preclinical therapeutic intervention to successfully avert the
pathologic process before widespread neurodegeneration.
However, knowledge of the pathophysiological processes dur-
ing this prodromal phase, and hence the ability to accurately
recognize or detect it, is still limited. Owing to technological
progress and global collaborative research in the field of ADimer’s Association. This is an open access article under the CC BY-NC-ND
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Project [IGAP]), our understanding of the genetic foundations
of AD is rapidly expanding. Genome-wide association studies
(GWAS) have resulted in the identification of 20 novel genetic
risk loci in addition to APOE ε4 [3–8], which have been
associated with a range of biological processes including
lipid metabolism, immune response, and synaptic processes.
The clinical utility of these findings for today’s patients, e.g.
in risk prediction, is still limited. Most of these risk factors
exert only minor effects on susceptibility to AD.
Combination of single single nucleotide polymorphisms
(SNPs) into a genetic risk score (GRS) has been proposed to
improve predictive ability, but in the absence of therapeutic
consequences, the clinical application of such a score will be
restricted. Nevertheless, there may already be a significant
purpose for genetic risk profiling. AD is a multifactorial and
heterogeneous condition. Genetic risk profiling can be used
for individual molecular subclassification, by determining
the pathways enriched for risk alleles within an individual.
This may increase the efficiency and outcome of clinical
trials and biomarker studies. In the long run, genetic risk
profiling could enable tailored treatment of each individual
with clinical AD. In addition, if genetic risk profiles are
predictive of specific clinical characteristics such as onset
age or speed of progression, this may aid decision making at
the clinical and personal level. For example, a high score on
an 8-SNP weighted genetic risk score (wGRSs) has been
associated with a two times more rapid progression from
mild cognitive impairment to AD [9].
We investigated the predictive ability of aGRS combining
APOE ε2/ε3/ε4 with the 20 most significant SNPs (CLU,
PICALM, CR1, ABCA7, MS4A6A, BIN1, CD2AP, CD33,
EPHA1, HLA-DRB5, PTK2B, SORL1, SC24A4-RIN3,
INPP5D, MEF2C, NME8, ZCWPW1, CELF1, FERMT2,
and CASS4 loci) identified in recent GWAS and IGAP as
well as a rare variant in TREM2 (p.R47H), which increases
risk of AD nearly fourfold [10–12] on a large,
well-characterized Flanders-Belgian AD study population,
part of which was previously included in the replication
phase of GWAS [3–6]. Our aim was twofold. First, we
aimed to determine the best discriminating model. Second,
we investigated to which extent this model can define
subgroups with shared phenotypic characteristics (familial
disease history, age at onset, and three cerebrospinal fluid
[CSF] biomarkers amyloid-b [Ab1–42], total tau (T-tau),
and tau phosphorylated at threonine 181 [P-tau181P]),
which may have additional value in clinical practice or
drug or biomarker development.2. Methods
2.1. Study population
The Flanders-Belgian patient group consisted of 1328
AD patients (mean age of onset 74.4 6 8.9 years, %
female 5 63.0), of which the majority was ascertained at theMemory Clinic of the ZNA Middelheim and Hoge Beuken,
Antwerp, Belgium (S.E. and P.P.D.D.) in the frame of a
prospective study of neurodegenerative and vascular dementia
in Flanders, the Dutch-speaking region of Belgium [13,14].
Another subset of patients was collected at the Memory
Clinic of the University Hospitals of Leuven (UHL),
Gasthuisberg, Leuven, Belgium (M.V. and R.V.) as part of a
prospective study on the molecular genetics of cognitive
impairment which was initiated in October 2006 using the
same clinical assessments and biosampling schemes. Each
patient underwent a neuropsychological examination and
structural and/or functional neuroimaging [15].
For a subset of patients (n 5 338; mean age at onset
76.2 6 8.5 years, 63% 5 women), CSF levels of Ab1–42,
T-tau, and P-tau181P were available as part of the diagnostic
work-up, determined with commercially available single
parameter ELISA kits (Fujirebio Europe, Ghent, Belgium).
The control group (n 5 1123, mean age at inclusion
64.96 13.7 years, 56%5 women) consisted of healthy un-
related individuals, without neurologic or psychiatric
antecedents or neurologic complaints or without organic
disease involving the central nervous system. Control indi-
viduals were examined at the Memory Clinic of ZNA Mid-
delheim and Hoge Beuken, Antwerpen, Belgium and at the
memory clinic at the University Hospitals of Leuven, Gas-
thuisberg, Leuven, Belgium. Additional community control
individuals were included after interview concerning medi-
cal and family history. Memory impairment was assessed
in all AD patients and control individuals by mini mental
state examination (MMSE) (control cohortMMSE.26; Fol-
stein et al.). Patients and control individuals originated from
the same geographical area (Flanders-Belgium). There is no
evidence of population substructure (Supplementary Fig. 1).
Part of the Flanders-Belgian Alzheimer (n 5 878) and
control (n5 661) population was included in the replication
phase of the IGAP [6].2.2. Ethical assurances
All participants and/or their legal guardian gave written
informed consent for participation in clinical and genetic
studies. Clinical study protocol and the informed consent
forms for patient ascertainment were approved by the Ethics
Committee of the respective hospitals at the cohort sampling
sites in Flanders-Belgium. The genetic study protocols and
informed consent formswere approved by theEthics Commit-
tees of the University of Antwerp and the University Hospital
of Antwerp, Belgium and the University Hospitals of Leuven,
Belgium. After informed consent, blood samples of patients
and control individuals were collected for genetic studies.2.3. Genotyping
We selected 22 polymorphisms to construct a GRS. This
included APOE ε2/ε3/ε4, TREM2 p.R47H, and 20 SNPs at
the AD risk loci identified in recent GWAS. At each locus,
Table 1
GRS models
Model Algorithm Number of SNPs APOE included APOE weight
APOE-S wGRS 1 1 Standard
APOE-A wGRS 1 1 Age-related
ALL-C cGRS 22 1 NA
ALL-WS wGRS 22 1 Standard
ALL-WA wGRS 22 1 Age-related
OTH-W wGRS 21 2 NA
Abbreviations: GRS, genetic risk score; SNPs, single nucleotide
polymorphisms; wGRS, weighted genetic risk score; NA, not applicable.
NOTE. The SNPs were combined by counting (cGRS), or weighted
(wGRS) allele algorithms. APOE was either included (1) or excluded
(2), and APOE weighting was done with standard [3] or age-related
weights [21].
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which each locus was first reported. Genotype data were
available from previous studies for APOE ε2/ε3/ε4,
TREM2 p.R47H [10], CLU rs11136000 [16], CR1
rs3818361 [17,18], and BIN1 rs744373 [19] on the full
cohort, and for PICALM rs3851179, CD33 rs3865444,
CD2AP rs9349407, ABCA7 rs3764650, MS4A6A
rs610932, EPHA1 rs11767557, HLA-DRB5 rs9271192,
PTK2B rs28834970, SORL1 rs11218343, SLC24A4-RIN3
rs10498633, INPP5D rs35349669, MEF2C rs190982,
NME8 rs2718058, ZCWPW1 rs1476679, CELF1
rs10838725, FERMT2 rs17125944, and CASS4 rs7274581
on part of the cohort (n 5 878 patients, n 5 661 control
individuals) [6]. Additional genotyping to generate genotype
data for the full cohort was for most SNPs performed by
MassARRAY using iPLEX Gold chemistry (Sequenom,
Hamburg, Germany), followed by MALDI-TOF mass
spectrometry. Polymerase chain reaction and extension
primers were designed using MassARRAY AssayDesign
software v3.0.2.0. Genotypes were called automatically
using MassARRAY Typer software v4.0 and were visually
inspected by two researchers blinded for disease outcome.
SNPs in PICALM, EPHA1, HLA-DRB5, SORL1, ZCWPW1,
and CELF1 were genotyped by Sanger sequencing. Primers
for these SNPs were designed with Primer-BLAST, and
sequences were analyzed by two independent researchers
using SeqMan or novoSNP [20]. Interplate controls showed
100% concordance for all SNPs. All selected SNPs had a
minor allele frequency .5% and were in Hardy-Weinberg
equilibrium in the control population (P . .001). Inhouse
genotyping and IGAP data showed 99.5% concordance.
An average genotyping success rate of 93.1% was obtained
over the 22 susceptibility genes.2.4. Statistical analyses2.4.1. Single SNP analyses
Allele frequencies of AD patients and control individuals
were compared using c2 statistics. Odds ratios (OR)
(calculated relative to the common genotype) and 95%
confidence intervals (CIs) were corrected for gender, APOE
ε4 genotype (presence of one or two APOE ε4 alleles vs. the
absence of any APOE ε4 allele), and age at onset (age at
inclusion for control individuals) using a logistic regression
model. Single SNP analyses were performed using SPSS
20.0 version for Windows (IBM SPSS Inc, Chicago, IL).
2.4.2. Genetic risk scores
Different GRSs were composed (Table 1). A counted
genetic risk score (cGRS) was derived by taking the sum
of risk alleles per individual (ModelALL-C). To account for
the strength of the genetic association of each allele, wGRSs
were derived by multiplying the number of risk alleles for
each SNP with the natural logarithm of their respective
OR (lnOR; based on discovery ORs [4,6,7,11] [Table 2])and taking the sum of these products per sample. Two
wGRSs were created, differing in how information about
APOE ε4 was incorporated. In the first scenario, the
contribution of APOE to the GRS was weighted by the
simple effect estimate of APOE ε4 on an independent AD
GWAS cohort of European ancestry (ModelALL-WS) [3]. In
the second scenario, weighting of APOE was based on
age-specific ORs for different APOE ε2/3/4 genotypes as
described by Genin et al. [21] to approximate the
known association between APOE ε4 and onset age
(ModelALL-WA).
After removing individuals with five or more missing
genotypes (166 patients and 104 control individuals), a
SNP score for missing genotypes was imputed by the
product of lnOR and the expected probability of having a
risk allele (briefly: 0 ! (12q)2 1 1 ! 2 (12q) q 1 2 !
q25 2q, where q equals the risk allele frequency). The final
data set available for GRS analyses comprised 1162 patients
and 1019 control individuals. To predict the discriminative
ability of the cGRS and wGRS for AD, receiver operating
characteristic (ROC) curves were generated with pROC in
R [22] by plotting the true positive rate against the false
positive rate and calculating the area under the curve
(AUC). Statistical comparison of ROC curves for different
models was performed with bootstrap analysis in a paired
or nonpaired approach, depending on the comparison of
GRS within or between groups. Stratification analyses
were performed for APOE and for familial history.
For APOE stratification, GRSs without APOE ε4
(ModelOTH-W) were compared between APOE-ε4
noncarriers and individuals carrying one or two APOE-ε4
alleles. For familial history stratification, GRSs were
compared between familial (FAD) and sporadic AD (SAD)
patients (ModelALL-WA and ModelOTH-W). Known
pathogenic mutation carriers in APP, C9orf72, PSEN1,
PSEN2, and GRN were excluded (n 5 16).
The relationship between the best GRS model
(ModelALL-WA) and risk of AD, FAD, and SADwas modeled
using logistic regression in R, using GRS as a continuous
predictor. In addition, individuals were partitioned into five
quantiles (quintiles) based on ModelALL-WA (with cutoffs
Table 2
Characteristics of the selected SNPs and allelic association in the Flanders-Belgian cohort
Gene SNP Published OR Minor allele Risk allele
Risk allele frequency
P value OR (95% CI) P valueControls Patients
APOE [3] rs7412, rs429358 2.53 ε4 ε4 0.14 0.32 1.0e27 3.23 (2.74–3.82) 1.0e27
CR1 [4] rs3818361 1.21 A A 0.19 0.22 .007 1.15 (0.97–1.36) .1
BIN1 [4] rs744373 1.17 G G 0.30 0.31 .5 1.24 (1.07–1.45) .005
CD2AP [7] rs9349407 1.14 C C 0.28 0.30 .2 1.10 (0.95–1.28) .2
ABCA7 [4] rs3764650 1.22 G G 0.09 0.11 .005 1.37 (1.09–1.72) .007
HLA-DRB5 [6] rs9271192 1.11 C C 0.26 0.30 .02 1.13 (0.96–1.33) .1
PTK2B [6] rs28834970 1.10 C C 0.36 0.39 .07 1.08 (0.93–1.26) .3
INPP5D [6] rs35349669 1.07 T T 0.47 0.48 .4 1.03 (0.89–1.18) .7
CELF1 [6] rs10838725 1.08 C C 0.32 0.34 .2 1.12 (0.96–1.31) .1
FERMT2 [6] rs17125944 1.13 C C 0.09 0.10 .1 1.03 (0.81–1.32) .8
TREM2 [11] rs75932628 4.50 T T 0.001 0.004 .08 4.41 (1.08–18.0) .04
EPHA1 [7] rs11767557 0.85 C T 0.81 0.82 .6 1.11 (0.93–1.32) .3
CLU [4] rs11136000 0.83 T C 0.60 0.63 .03 0.82 (0.71–0.94) .006
MS4A6A [4] rs610932 0.88 T G 0.58 0.60 .1 0.92 (0.80–1.06) .3
PICALM [4] rs3851179 0.87 T C 0.65 0.68 .06 0.84 (0.72–0.98) .02
CD33 [7] rs3865444 0.88 A C 0.69 0.69 .6 0.96 (0.83–1.12) .6
SORL1 [6] rs11218343 0.76 C T 0.95 0.96 .006 0.67 (0.47–0.96) .03
SLC24A4 [6] rs10498633 0.90 T G 0.80 0.79 .3 1.08 (0.90–1.29) .4
MEF2C [6] rs190982 0.92 G A 0.59 0.61 .4 0.94 (0.81–1.08) .4
NME8 [6] rs2718058 0.93 G A 0.62 0.63 .7 1.00 (0.86–1.16) 1.0
ZCWPW1 [6] rs1476679 0.92 C T 0.66 0.71 .001 0.80 (0.69–0.94) .005
CASS4 [6] rs7274581 0.87 C T 0.91 0.92 .2 0.84 (0.64–1.09) .2
Abbreviations: SNPs, single nucleotide polymorphisms; OR, odds ratio; CI, confidence interval.
NOTE. Selected SNPs are presented with their published discovery odds ratios (OR), given for the minor allele. For APOE, OR was calculated within the
Flanders-Belgian population. Frequency of the risk alleles, which are included in GRS models, is presented for Flanders-Belgian patients and controls, along
with a nominal P value based on c2 statistics. The OR and 95% confidence interval (95% CI) obtained in the Flanders-Belgian cohort are given for the minor
allele and are adjusted for APOE ε4 status (for all SNPs except APOE genotype itself), age at onset or inclusion, and gender.
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FAD, SAD, and control subjects was evaluated for each fifth.
ORs and 95% CIs for disease outcome were calculated per
fifth with the third group, containing the 20% average scores
in this study, as the reference. Graphical display of results
was performed using plotrix in R [23].
To evaluate risk profile redundancy, wGRSs comprising
subsets of variants were generated. Risk factors were ranked
based on their discovery ORs in independent cohorts
[4,6,7,11]. Cumulative scores of variants with decreasing
impact were then calculated on the Flanders-Belgian cohort
and subjected to ROC-curve evaluation. Comparison
between these reduced models was done with paired
bootstrap analysis.
The relationship between the GRS and AD-related
endophenotypes (onset age and CSF biomarker levels
Ab1–42, T-tau, and P-tau181P) was assessed in linear
regression models in R. For the CSF biomarker analyses,
ModelALL-WA was used as a predictor variable. T-tau and
P-tau were log10 transformed to approximate normality.
Covariates age and disease duration at lumbar puncture
were evaluated in a stepwise procedure, resulting in
exclusion from the final regression model for all three
biomarkers. For onset age analyses, ModelALL-WS without
age-specific weights for APOE genotypes was used as
a predictor variable to allow correlation analysis with
onset age.3. Results
3.1. Single SNP associations in the Flanders-Belgian AD
cohort
We included 22 polymorphisms in this study, which were
previously implicated in AD risk (Table 2; Table S1). Seven
polymorphisms (at APOE, CR1, ABCA7, SORL1, ZCWPW1,
HLA-DRB5, and CLU) showed nominal evidence of associa-
tion with AD in the full Flanders-Belgian study cohort and
eight polymorphisms remained (APOE, ABCA7, SORL1,
ZCWPW1, and CLU) or became (BIN1, TREM2, and PIC-
ALM) nominally significantly associated after adjusting for
age, gender, and APOE ε4 status. Only APOE ε4 would be
considered significant after Bonferroni correction for 22 tests.3.2. GRS model comparisons
We composed four different GRS models (Table 1) and
compared them against each other aswell aswith the discrim-
inative ability of two models based on APOE genotype alone
(Fig. 1A). The AUC based on the weighted alleles of APOE
ε4 only (ModelAPOE-S) was 0.65. The discriminative ability
of APOE improved when taking into account age-specific
weights for the different APOE genotypes (ModelAPOE-A;
AUC 5 0.67, P 5 5.2e29). ModelALL-C, which was derived
by the sum of risk alleles at the 22 polymorphisms, had less
discriminative ability toward disease outcome in the
Fig. 1. Comparison of the discriminative ability of different models of GRS for AD. (A) Receiver operating characteristic (ROC) curves for the six GRSmodels
detailed in Table 1, based on the AD and control cohort. Area under the curve (AUC) for APOE-S: 0.65, APOE-A: 0.67; ALL-WA: 0.70; ALL-WS: 0.68;
ALL-C: 0.60, and OTH-W: 0.58. (B) Odds ratios (OR) of AD are presented with 95% confidence intervals (CI) for each quantile of ModelALL-WA, with
the third (20% average GRS) quantile as reference. The x-axis gives numbers for increasing quantiles. *denotes a P value of ,1.0e215 based on
Cochran-Armitage test for trend. Abbreviations: GRS, genetic risk score; AD, Alzheimer’s disease; wGRS, weighted genetic risk score.
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ModelAPOE-A, with an AUC of 0.60. The inclusion of
weights for strength of associations in the full GRS models
(wGRSs) resulted in ameliorated prediction as expected
(ModelALL-C vs. ModelALL-WA; P ,1.0e
215). In line with
the results of the two APOE models, ModelALL-WA, which
takes into account age-specific weights for APOE, resulted
in a slight but significant improvement of AUC compared
with the simple weighted ModelALL-WS (0.70 vs. 0.68,
P 5 2.0e26). The predictive potential of a model including
21 SNPs without APOE (ModelOTH-W, AUC 5 0.58) was
less than that of APOE but the SNPs did have a significant
added value when combined with APOE (ModelALL-WA
vs. ModelAPOE-A; P 5 2.8e
26). Stratification by APOE
did not reveal significant differences in ROC cur-
ves for ModelOTH-W comprising the 21 other variants
(AUCAPOE ε42 5 0.57 vs. AUCAPOE ε41 5 0.59, P 5 .4;
Supplementary Figure 2).
Logistic regression analysis using the best GRS
(ModelALL-WA) showed an increased risk of AD with
increasing risk score (OR, 2.32 [95% CI, 2.08–2.58] per
unit increase on the GRS; Z-statistic 15.3, P ,1.0e215).
On quintile partitioning, individuals in the highest fifth had
an OR of 5.69 (95% CI, 4.17–7.75) of AD compared with
the center group (Fig. 1B).
A parsimony analysis indicated that a reduced model,
including only 16 variants and age-related APOE weights, re-
sulted in similar discriminative ability as a full wGRS model.
The AUC of this parsimonious model (0.70) was comparable
with ModelALL-WA (AUC 5 0.70; P 5 .2; Supplementary
Fig. 3).3.3. GRS and family history of AD
The discriminative ability of GRS ModelALL–WA toward
disease outcome was significantly higher in AD patientswith a positive family history (AUCFADvsCon 5 0.78;
AUCSADvsCON 5 0.68 [P 5 1.7e
25]; Fig. 2A). Although
much of the discriminative ability was attri-
butable to APOE (ModelAPOE-A; AUCFADvsCON 5 0.76;
AUCSADvsCON 5 0.65 [P 5 5.6e
27]) and the AUCs for
FAD and SAD were not significantly different for
ModelOTH-W, the 21 genes had a significant added
value when combined with APOE in FAD patients
(P5 .01) as well as in SAD patients (P5 5.5e28) in contrast
to APOE only (Fig. 2A).
Risk of AD increased with increasing GRS for both FAD
and SAD but the risk increased more strongly for FAD (OR,
3.01 [95% CI, 2.55–3.58] per unit increase onModelALL-WA;
Z-statistic, 12.7; P,1.0e215) than for SAD (OR, 2.14 [95%
CI, 1.92–2.40]; Z-statistic, 13.3; P ,1.0e215). The propor-
tion of familial and sporadic Alzheimer patients was the
highest in the highest risk quantiles of ModelALL-WA
(Fig. 2B). In total, 41% of all patients with a positive family
history had a wGRS .4.31, as opposed to only 8% of all
control subjects (Fig. 2B). Patients in the upper quantile
had an OR, 2.03 (95% CI, 1.27–3.27) of having a familial
history of AD compared with patients in the center quantile.3.4. GRS—endophenotype correlations
The GRS was negatively correlated with onset age
(Pearson r 5 20.20, P 5 9.0e211; Fig. 3). Onset age
decreased with 2.39 years (standard error [SE], 0.36;
P ,1.0e27) per unit increase in risk score. Patients in the
lower quantile had a median onset age of 80 years compared
with 74 years in the upper quantile (P 1.3e27). To evaluate
the influence of APOE, additional analysis was performed
based on ModelOTH-W. The combined score of the 21 genes
remained significantly correlated with a decreasing age at
onset (Pearson r 5 20.12, P 5 .0001) after exclusion of
APOE.
Fig. 2. GRS and family history of AD. (A) ROC curves for familial AD (FAD) patients (defined by at least one first degree relative with dementia, n 5 206)
versus controls and sporadic AD (SAD) patients (n 5 899) versus controls. ROC curves for FAD based on ModelALL-WA (black curve; AUC 5 0.78) and
ModelAPOE-A (green curve; AUC 5 0.76); ROC curves for SAD based on ModelALL-WA (red; AUC 5 0.68) and ModelAPOE-A (blue; AUCAPOE 5 0.65).
(B) The percentage of familial AD (blue, n5 206), sporadic AD patients (red, n5 899), and control subjects (green, n5 1019) is shown per quantile. **denotes
a P value of ,1.0e215 based on Cochran-Armitage test for trend when comparing FAD to SAD patients; *OR, 2.03 (95% CI, 1.27–3.27; P, .004) for positive
family history of AD when comparing the upper fifth with the center fifth. Abbreviations: GRS, genetic risk score; AD, Alzheimer’s disease; ROC, receiver
operating characteristic; AUC, area under the curve; OR, odds ratio; CI, confidence interval.
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(ModelALL-WA) and CSF Ab1–42 levels in patients but not
T-tau or P-tau181P (Fig. 4A–C). The GRS was negatively
correlated with Ab1–42 concentrations in CSF (Pearson
r 5 20.28, P 5 8.9e27). Ab1–42 decreased with 49.9 pg/
mL (SE 10.6) per unit increase on the GRS (P 5 4.0e26)
and had a median value of 531 pg/mL in the lower quantile
and 399.5 pg/mL in the upper quantile (P 5 .001). After
exclusion of APOE from the GRS, however, this correla-
tion was no longer significant (Pearson r 5 20.071,
P 5 .1). In contrast, the 21-SNP GRS excluding APOE
(ModelOTH-W) appeared correlated with log10T-tau (Pear-
son r 5 0.11, P 5 .03) and log10P-tau181P (Pearson
r 5 0.11, P 5 .04).Fig. 3. Negative correlation between GRS and onset age in patients.
Scatterplot of onset age (y-axis) and GRS (x-axis). A regression line is
presented with 95% CI. The association between onset age and GRS
was determined using ModelALL-WS without incorporated age weights.
Abbreviations: GRS, genetic risk score; CI, confidence interval.4. Discussion
In this study, 22 AD susceptibility loci were combined to
explore the potential of GRSs in AD. Except for APOE,
these individual variants only have a marginal contribution
toward disease prediction, but when combined, they result
in a better risk profile than based on APOE alone. When
combining genotype data on all 22 variants, best discrimina-
tion between patients and control individuals was achieved
by a wGRS with age-related weighting of APOE genotypes
(ModelALL-WA). As expected, wGRS outperformed the
cGRS, given that the latter model does not take into account
the stronger risks conveyed by APOE ε4 and TREM2
p.R47H [24,25]. There were no notable differences in
genetic risk profile in the presence or absence of APOE ε4
in our study population.
Parsimony analysis demonstrated the potential of reduced
models to have equal predictive value of disease outcome.
This can be especially interesting in a clinical context where
the aim is to capture as much information as possible, while
limiting the cost and labor of genotyping.
It should be noted that determination of parsimonious
models may be population-specific, because of differences
in allele frequencies, patterns of linkage disequilibrium,
and interactions. In addition, in the context of personal-
ized medicine and given the diversity of pathophysiolog-
ical pathways contributing to AD susceptibility,
parsimonious profiles might omit relevant information.
The findings of the parsimony analysis are not fully
unexpected, given the diminishing effect sizes of loci
detected due to increasingly large study cohorts and
suggest that there may be limited gain in future
performance of the GRS by inclusion of new indirectly
associated SNPs with small ORs.
Fig. 4. GRS-CSFbiomarker correlations. Scatterplots ofGRSModelALL-WA
with patient CSF concentrations of (A) Ab1–42, (B) T-tau, and (C) P-tau181P.
Regression lines are presented with 95% CI. Abbreviations: GRS, genetic
risk score; CSF, cerebrospinal fluid; CI, confidence interval.
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population, with sensitivity of 55% and specificity of 78%
at its point of balanced accuracy [26] and maximum
potential effectiveness (Youden index [27]). In comparison,
a CSF biomarker panel comprising Ab1–42 and T-tau and
P-tau181P can discriminate autopsy-confirmed AD from
cognitively healthy elderly with a sensitivity of 86% and
a specificity of 89% [28]. Particularly in light of the current
lack of preventive or therapeutic consequences, these GRSs
have limited utility in risk prediction. Nevertheless, the
marked increase in risk of AD with increasing GRS, as
well as the GRS-endophenotype correlations, identify a
potential toward application at the shorter term. Individualswith the 20% highest scores (score .4.31) were at a
substantial, fivefold, increased risk to develop AD
compared with individuals with the 20% average scores.
Moreover, this group had a significantly lower onset age,
even when excluding the known effect of APOE ε4 on onset
age. The ability to genetically determine this high risk
profile may be of value to expedite drug and biomarker tri-
als, which are shifting their focus toward prodromal phases
of AD.
CSF Ab1–42 decreased with increasing GRS, but this
appeared to be driven by APOE ε4. This suggests that there
may be added benefit from a combined genetic and CSF risk
profile, as the GWAS loci appear to capture pathophysiolo-
gical processes other than Ab pathology. The value of
more complex risk profiling incorporating additional
nongenetic information is demonstrated by the fact that the
model including age-specific effects for APOE performed
better than a model ignoring this information.
Interestingly, the discriminative ability of the GRS was
stronger when limiting the analysis to patients with a
positive family history. As expected, much of the predictive
power came from APOE. Nonetheless, adding the 21
susceptibility genes to the risk model significantly improved
its discriminative ability. The risk of FAD increased even
more strongly with increasing GRS than risk of SAD. This
suggests that part of the familial aggregation of AD can be
explained by a high combined SNP risk score. We cannot
exclude that de novomutations or recessive causes of disease
exist in the SAD cohort which may have diluted the
discriminative ability of the GRS in SAD; however, we do
not expect this to have a large effect given the most likely
rare events of de novo mutation and recessive AD. Future
studies are warranted to address the ability of the GRS to
predict—in individuals with a positive family history of
AD—who eventually becomes affected.
Although not ready for clinical application, GRSs are a
promising method to identify individuals at high risk which
may facilitate therapeutic or biomarker trials. Future
directions include improvement of GRSs with novel
functional variants and comparing and combining genetic
profiles with CSF or plasma-based biomarkers.Acknowledgments
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1. Systematic review: We included all independently
replicated genetic risk loci from large-scale
genome-wide association studies and next genera-
tion sequencing studies on AD identified through
systematic search of PubMed.
2. Interpretation: A GRS for AD based on current
knowledge has limited utility to predict AD, but this
study illustrates that incorporation of nongenetic infor-
mation, such as age-specific effect estimates forAPOE
ε4, can improve the discriminative ability. This study
highlights the feasibility to identify individuals at
highest susceptibility. This enables genetic preselec-
tion to streamline biomarker and drug trials and may
aid clinical and personal decision making.
3. Future directions: Identification of novel loci and
variants will further increase the discriminative
ability, but it may be important to combine a GRS
with environmental and biomarker data. For
biomarker and drug trials, a genetic risk profile
ideally should be pathway-based. This will require
pinpointing the culprit genes underlying extended
genome-wide association signals.References
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